Economic burden of uncomplicated urinary tract infections: direct, indirect and intangible costs.
Economic burden of uncomplicated urinary tract infections: direct, indirect and intangible costs.
复制标题
DOI：
10.1586/14737167.5.4.457
复制
发表时间：
2005-08-01
影响因子：
2.3
通讯作者：
Subedi, Prasun
中科院分区：
文献类型：
--
作者：
Keating, Karen N;Perfetto, Eleanor M;Subedi, Prasun
更好地了解抗菌疗法如何影响降低无并发症尿路感染的总成本，包括直接成本（例如就诊）、间接成本（例如生产力）和无形成本（例如疼痛）将有助于选择最佳治疗方法。该文献综述的结果表明，单纯性尿路感染造成了相当大的社会负担，1995 年间接成本约为 10 亿美元，直接成本超过 6 亿美元。然而，没有一项已确定的研究纳入了所有三个成本组成部分，对当前这些成本程度的了解存在空白，并且没有基于总成本的比较评估。需要进行研究以提供关于单纯性尿路感染的直接、间接和无形成本负担的最新见解。
A better understanding of how antimicrobial therapies affect the total cost of lower uncomplicated urinary tract infection, including direct (e.g., doctor visits), indirect (e.g., productivity) and intangible (e.g., pain) costs would facilitate selection of an optimal therapeutic approach. The results of this literature review indicate that the there is a considerable societal burden from uncomplicated urinary tract infection, with approximately USD 1 billion in indirect and over USD 600 million in direct costs in 1995. However, no single identified study incorporated all three cost components, there are gaps in the knowledge concerning the current extent of these costs, and there are no comparative assessments based on total cost. Research is needed to provide current insights on the burden of uncomplicated urinary tract infection in terms of direct, indirect and intangible costs.